文献速递血栓与止血

血友病基因治疗:临床获益、局限与遗留问题综述

Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues.
PubMed 文献 · Blood · 2021-01-01

本综述总结了近十年血友病A和B基因治疗的进展,聚焦已发表和正在进行的临床试验结果。多数使用AAV载体的研究显示,重型血友病患者凝血因子VIII和IX表达足以显著减少出血次数和预防治疗需求,但副作用和缺陷仍需解决才能广泛推广。

要点

  • AAV载体肝导向基因治疗可显著减少重型血友病患者的出血和预防治疗需求。
  • 近期1期及2b/3期试验初步结果支持基因治疗的临床获益。
  • 副作用和缺陷仍是基因治疗广泛应用的障碍,需进一步解决。

核心结论

  • 基因治疗在血友病A和B中已取得巨大进展,多数患者获得显著临床获益,但副作用和遗留问题仍需解决才能广泛应用。

研究设计与样本

  • 综述总结已发表和正在进行的基因治疗试验,重点关注近期报告的1期试验结果及2b/3期试验初步结果。

主要发现

  • 2011年首次报告静脉给予AAV肝导向基因治疗重型血友病B的鼓舞性结果后,许多基因治疗研究启动。
  • 多数使用不同基因构建的AAV载体的研究显示,患者凝血因子VIII和IX表达足以显著减少出血次数和预防治疗需求。
  • 几乎所有患者获得显著临床获益,但新报告也揭示了副作用和缺陷的影响。

临床怎么用

  • 基因治疗可为重型血友病患者显著减少出血和预防治疗需求,但需关注副作用和缺陷,广泛推广前需解决遗留问题。

局限性

  • 基因治疗相关副作用和缺陷仍需解决,当前方法尚未广泛适用于血友病患者群体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the last decade, enormous progress has been made in the development of gene therapy for hemophilia A and B. After the first encouraging results of intravenously administered adeno-associated virus (AAV)-based liver-directed gene therapy in patients with severe hemophilia B were reported in 2011, many gene therapy studies have been initiated. Most of these studies, using AAV vectors with various gene constructs, showed sufficient factor VIII and IX expression in patients to significantly reduce the number of bleeds and the need for prophylaxis in most patients with severe hemophilia. This resulted in great clinical benefit for nearly all patients. In this review, we will summarize the most recent findings of reported and ongoing gene therapy trials. We will highlight the successful outcome of trials with focus on the results of recently reported phase 1 trials and preliminary results of phase 2b/3 trials for hemophilia A and B. These new reports also reveal the impact of side effects and drawbacks associated with gene therapy. We will therefore also discuss the limitations and remaining issues of the current gene therapy approaches. These issues must be resolved before gene therapy will be widely available for the hemophilia patient population.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Leebeek FWG, Miesbach W. Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues. Blood. 2021. PMID: 34232980. doi:10.1182/blood.2019003777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。